Topics

BJ Bio Selects CMAB for CMC and Manufacturing of Cancer mAb

02:13 EDT 12 Oct 2019 | ChinaBio Today

BJ Bioscience, a Hangzhou novel drug developer, has signed up CMAB Biopharma (Suzhou) to provide CMC research and manufacturing services for BJ-005, its bi-functional mAb intended for cancer indications. CMAB will develop BJ-005 to support INDs in China and the US. Previously, BJ Bio has submitted an IND for its lead candidate, BJ-105, a fusion IL-12 mAb, also targeting cancer. The company said it wants to focus on innovative discovery, while it uses CMAB's experience in CMC and manufacturing to advance BJ-005. More details....

Share this with colleagues:

Original Article: BJ Bio Selects CMAB for CMC and Manufacturing of Cancer mAb

NEXT ARTICLE

More From BioPortfolio on "BJ Bio Selects CMAB for CMC and Manufacturing of Cancer mAb"

Quick Search

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...